KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Change in Cash (2016 - 2025)

Historic Change in Cash for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $162.8 million.

  • West Pharmaceutical Services' Change in Cash rose 268412.7% to $162.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $306.7 million, marking a year-over-year increase of 18304.9%. This contributed to the annual value of $306.7 million for FY2025, which is 18304.9% up from last year.
  • Per West Pharmaceutical Services' latest filing, its Change in Cash stood at $162.8 million for Q4 2025, which was up 268412.7% from $118.8 million recorded in Q3 2025.
  • In the past 5 years, West Pharmaceutical Services' Change in Cash registered a high of $165.3 million during Q4 2022, and its lowest value of -$252.1 million during Q1 2024.
  • In the last 5 years, West Pharmaceutical Services' Change in Cash had a median value of $27.6 million in 2022 and averaged $8.8 million.
  • In the last 5 years, West Pharmaceutical Services' Change in Cash tumbled by 305125.0% in 2024 and then skyrocketed by 268412.7% in 2025.
  • Over the past 5 years, West Pharmaceutical Services' Change in Cash (Quarter) stood at $74.6 million in 2021, then skyrocketed by 121.58% to $165.3 million in 2022, then tumbled by 127.04% to -$44.7 million in 2023, then skyrocketed by 85.91% to -$6.3 million in 2024, then soared by 2684.13% to $162.8 million in 2025.
  • Its last three reported values are $162.8 million in Q4 2025, $118.8 million for Q3 2025, and $105.5 million during Q2 2025.